Greenwich LifeSciences Shares Rise After EMA Clears Commercial GP2 for FLAMINGO-01 Trial
Shares of Greenwich LifeSciences climbed after the European Medicines Agency approved the use of commercially manufactured GP2 in the company's Phase III FLAMINGO-01 trial. The authorization permits the same GP2 lot to be used across US and European clinical sites, shipments to European pharmacies have started, and the trial's non-HLA-A02 arm shows…